NCT00961571 2025-02-12
Sunitinib and Capecitabine for First Line Colon Cancer
Georgetown University
Phase 2 Terminated
Clinical Trials
62 trialsNCT01254864 2025-01-27
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03109015 2024-10-08
ASSET
Duke University
Phase 2 Completed
NCT01517243 2023-09-21
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00656669 2023-05-23
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
Indiana University
Phase NA Completed
NCT00520533 2022-10-12
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT01164202 2022-03-18
SATURNE
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT00695292 2021-11-22
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT02164240 2021-06-14
SURE
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01185366 2021-04-28
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00853125 2021-04-27
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00668811 2020-08-05
IIT Sutent
Medstar Health Research Institute
Phase 2 Completed
NCT00905021 2020-07-24
EXTENT
Baylor Breast Care Center
Phase 1/2 Terminated
NCT02060370 2020-02-27
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00616122 2020-01-13
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
University of California, San Francisco
Phase 1/2 Terminated
NCT00859456 2019-11-04
Sunitinib in Certain Subtypes of Soft Tissue Sarcomas
Columbia University
Phase 2 Terminated
NCT00794950 2019-09-23
Sutent
University of Michigan
Phase 2 Completed
NCT00513695 2019-08-07
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
Phase 2 Completed
NCT01118351 2019-05-01
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00526656 2019-04-16
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01502228 2019-03-05
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
Indiana University
Phase NA Terminated
NCT01829217 2018-10-31
Sunitinib in Never-Smokers With Lung Adenocarcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01158222 2018-09-14
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00768144 2018-08-24
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00891878 2018-07-24
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00463060 2018-07-18
Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT00824538 2018-04-05
Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow
University of California, San Francisco
Phase 2 Terminated
NCT01042795 2017-06-28
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
University of Michigan
Phase 2 Terminated
NCT00537056 2017-06-14
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
Stanford University
Phase NA Completed
NCT00524316 2017-05-09
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00425386 2017-05-03
Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00519896 2017-04-25
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
University of Washington
Phase 2 Completed
NCT00702884 2017-03-21
Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00730353 2017-03-16
Sutent + Taxol for Advanced Esophageal Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00879619 2017-02-01
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
University of California, Irvine
Phase 1/2 Terminated
NCT00577382 2016-12-08
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00887575 2016-09-07
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00465179 2016-06-07
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00556049 2016-04-21
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT00912912 2016-04-15
Sunitinib Malate in Refractory Germ Cell Tumors
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00859339 2016-04-14
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00847015 2016-02-29
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00397488 2016-01-25
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00474994 2016-01-20
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00734851 2015-12-23
Multimodality Phase II Study in Prostate Cancer
Duke University
Phase 2 Terminated
NCT00694096 2015-12-01
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
University of Utah
Phase 1 Completed
NCT00459875 2015-11-26
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed